Educational video
If the embedded player shows extra content, use the direct video link above; we keep the embed for easy viewing.
What it is
Atrial flutter (AFL) is a macro‑reentrant atrial tachycardia with organized atrial activation (often ~240–340 bpm). The ventricular rate depends on AV node conduction; a classic presentation is 2:1 AV conduction with a pulse around 150 bpm.
Typical vs atypical flutter
- Typical (CTI‑dependent): reentry around the tricuspid annulus using the cavotricuspid isthmus (CTI) — highly ablation‑curable.
- Atypical: non‑CTI macro‑reentry (often left atrial; scar‑related or post‑AF ablation) — may require advanced mapping and has more variable outcomes.
Incidence and who gets it
- Incidence rises steeply with age; male predominance is consistent in population data.
- Heart failure and COPD increase risk in population cohorts.
- AFL frequently coexists with atrial fibrillation (AF), and AF may appear after successful flutter ablation.
See the references table for the key epidemiology cohort (Granada et al., JACC 2000).
Causes, triggers, and risk factors
Structural substrate
Hypertension, atrial dilation, valvular disease, cardiomyopathy, heart failure.
Pulmonary / hypoxia
COPD, sleep apnea, hypoxia; pulmonary disease can promote atrial remodeling.
Electrophysiology / scar
Post‑cardiac surgery or post‑ablation scars predispose to atypical flutter circuits.
Lifestyle / acute triggers
Alcohol binges, stimulants, dehydration, acute illness, thyroid disease.
Symptoms and red flags
- Palpitations, breathlessness, fatigue, dizziness, exercise intolerance.
- Can precipitate angina or decompensated heart failure (tachycardia‑mediated cardiomyopathy in sustained cases).
- Emergency red flags: fainting, ongoing chest pain, severe breathlessness/pulmonary edema, hypotension/shock.
Investigations EPs usually order
- 12‑lead ECG (diagnosis and flutter type clues).
- Echocardiogram (LV function, atrial size, valves).
- Labs: electrolytes, thyroid (TSH), CBC where appropriate.
- Consider sleep apnea assessment when risk factors present.
- If cardioversion is planned and duration >48h/unknown: anticoagulation strategy and/or TEE to exclude atrial thrombus.
Treatment Options
- Medications: Rate control (beta blockers, calcium channel blockers) and, in selected cases, rhythm control agents.
- Cardioversion: Electrical cardioversion can restore rhythm quickly (often used when symptoms are significant).
- Catheter ablation: Definitive therapy for typical CTI-dependent flutter by creating bidirectional CTI block.
Cardioversion – Risks & Considerations
Electrical cardioversion restores normal rhythm by delivering a synchronized shock under sedation/anaesthesia.
Main risks
- Stroke / embolism: If a clot is present in the atrium/appendage, restoring rhythm can dislodge it. To reduce risk, clinicians use anticoagulation (often for weeks if duration is uncertain) and/or transesophageal echocardiography (TEE) to exclude clot before cardioversion.
- Skin irritation/burns: Usually mild at pad sites (uncommon).
- Recurrence: Flutter can recur if the underlying circuit is still present.
- Sedation-related risks: Low in monitored settings, but can include low blood pressure and breathing suppression.
Key point: Cardioversion restores rhythm but does not remove the CTI circuit. Definitive cure for typical flutter is usually catheter ablation.
Evidence snapshot
Below is a concise evidence list; the full table is on the References page.
| Journal | Study type | Key finding (why it matters) | Link |
|---|---|---|---|
| J Am Coll Cardiol (JACC) | Population-based cohort (epidemiology) | Overall incidence 88/100,000 person‑years; rises sharply with age; ~2.5× higher in men; HF and COPD increase risk. | Open |
| Circulation: Arrhythmia and Electrophysiology | Outcomes study (technique / recurrence) | Long‑term outcomes after CTI ablation; larger tip/irrigated RF associated with lower flutter recurrence (e.g., ~6.7% vs 13.8%). | Open |
| JACC: Clinical Electrophysiology | Systematic review & meta‑analysis | Quantifies incidence of atrial fibrillation after successful typical flutter ablation (AF remains common over follow‑up). | Open |
| Europace | Cohort (new‑onset AF after CTI) | New‑onset AF develops in a significant proportion after CTI ablation; caution about stopping anticoagulation solely because flutter is ablated. | Open |
| Circulation | Randomized trial (strategy in AF+AFL) | In patients with AF plus typical flutter, randomized comparison of pulmonary vein–LA junction disconnection strategy vs standard approaches (strategy paper). | Open |
| Heart Rhythm | Prospective randomized trial | Tests hypothesis that pulmonary vein triggers may initiate AFL/AF; evaluates PVI strategy in patients with typical flutter without prior AF. | Open |
| JAMA | Randomized trial (ablation vs AAD; AF context) | Radiofrequency ablation vs antiarrhythmic drugs reduced recurrent atrial tachyarrhythmias at 2 years (high‑impact RCT supporting ablation). | Open |
| N Engl J Med | Randomized trial (energy modality; AF context) | ADVENT: pulsed‑field ablation noninferior to thermal ablation for paroxysmal AF (relevant to energy technologies discussed in EP labs). | Open |
| Europace | Guideline document (ESC) | ESC guidance for AF/AFL management including anticoagulation around cardioversion and rhythm control frameworks. | Open |
| J Am Heart Assoc (JAHA) | Epidemiology / genetics (atrial arrhythmia predisposition) | Large cohort work addressing associations and predisposition signals in atrial arrhythmias (context for genetics section). | Open |